U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of LRTD and severe LRTD caused by RSV…

Read MoreU.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age

Increasing access to lifesaving treatments: How Humira® biosimilars will reshape the healthcare industry

Biosimilars are medications that are highly similar to U.S. Food and Drug Administration (FDA)-approved reference biologics – the fastest-growing class of drugs in the U.S., bringing innovative, life-changing treatments to patients with cancer and chronic diseases. Biologics are made from living…

Read MoreIncreasing access to lifesaving treatments: How Humira® biosimilars will reshape the healthcare industry

Immunis is a Finalist for the High Tech Award for “Best Emerging Technology Company”

Immunis, Inc., a private biotech and a leading innovator in cellular secretome therapies for age and disease-related immune decline, is honored to be selected as a finalist for the “Best Emerging Technology Company” by the Octane High Tech Awards (HTA). The HTA awards…

Read MoreImmunis is a Finalist for the High Tech Award for “Best Emerging Technology Company”

Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria

Novartis today announced positive top-line results from the Phase III REMIX-1 and REMIX-2 studies evaluating remibrutinib 25 mg b.i.d., a Bruton’s tyrosine kinase (BTK) inhibitor, in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines1. Both…

Read MoreNovartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria

Henry Schein Opens Customer Assistance Hotline in Response to Hawaii Wildfires

Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers in Hawaii that the Henry Schein Customer Assistance Hotline is open for dentists and physicians who may experience operational, logistical, or financial issues as a result of damage caused by the recent wildfires. The toll-free…

Read MoreHenry Schein Opens Customer Assistance Hotline in Response to Hawaii Wildfires